Evidence map›Paper›PMID 35917201›Full record

ArticleCancer2022

Improved survival in cervical cancer patients receiving care at National Cancer Institute-designated cancer centers.

Corinne McDaniels-Davidson, Christine H Feng, Maria Elena Martinez, Alison J Canchola, Scarlett Lin Gomez, Jesse N Nodora, Sandip P Patel, Arno J Mundt, Jyoti S Mayadev

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Disparities in Gynecologic Cancers.Cancer journal (Sudbury, Mass.)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Corinne McDaniels-DavidsonSchool of Public Health, San Diego State University, San Diego, California, USA.ORCID 0000-0002-4062-7532
Christine H FengMoores Cancer Center, University of California San Diego, La Jolla, California, USA.
Maria Elena MartinezMoores Cancer Center, University of California San Diego, La Jolla, California, USA.
Alison J CancholaDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Scarlett Lin GomezDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Jesse N NodoraMoores Cancer Center, University of California San Diego, La Jolla, California, USA.
Sandip P PatelMoores Cancer Center, University of California San Diego, La Jolla, California, USA.
Arno J MundtMoores Cancer Center, University of California San Diego, La Jolla, California, USA.
Jyoti S MayadevMoores Cancer Center, University of California San Diego, La Jolla, California, USA.
University of California San Diego · USUniversity of California, San Francisco · USSan Diego State University · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Research Education CoreU54CA132384 · NCI · SAN DIEGO STATE UNIVERSITY · PI CRIPPS, RICHARD MATTHEW, CROWE, SHEILA E. · 2008 to 2022
$20.7M
Research Education CoreU54CA132379 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARREDONDO, ELVA M, CROWE, SHEILA E. · 2008 to 2021
$16.1M
NCI NIH HHS P30 CA023100NCI NIH HHS U54 CA132379NCI NIH HHS U54 CA132384
6 · The paper itself

Abstract

backgroundLocally advanced cervical cancer (CC) remains lethal in the United States. We investigate the effect of receiving care at an National Cancer Institute-designated cancer center (NCICC) on survival.

methodsData for women diagnosed with CC from 2004 to 2016 who received radiation treatment were extracted from the California Cancer Registry (n = 4250). Cox proportional hazards regression models assessed whether (1) receiving care at NCICCs was associated with risk of CC-specific death, (2) this association remained after multivariable adjustment for age, race/ethnicity, and insurance status, and (3) this association was explained by receipt of guideline-concordant treatment.

resultsMedian age was 50 years (interquartile range [IQR] 41-61 years), with median follow-up of 2.7 years (IQR 1.3-6.0 years). One-third of patients were seen at an NCICC, and 29% died of CC. The hazard of CC-specific death was reduced by 20% for those receiving care at NCICCs compared with patients receiving care elsewhere (HR = .80; 95% CI, 0.70-0.90). Adjustment for guideline-concordant treatment and other covariates minimally attenuated the association to 0.83 (95% CI, 0.74-0.95), suggesting that the survival advantage associated with care at NCICCs may not be due to receipt of guideline-concordant treatment.

conclusionsThis study demonstrates survival benefit for patients receiving care at NCICCs compared with those receiving care elsewhere that is not explained by differences in guideline-concordant care. Structural, organizational, or provider characteristics and differences in patients receiving care at centers with and without NCI designation could explain observed associations. Further understanding of these factors will promote equality across oncology care facilities and survival equity for patients with CC.

Indexed as

Uterine Cervical NeoplasmsAdultEthnicityFemaleHumansMiddle AgedNational Cancer Institute (U.S.)Proportional Hazards ModelsRegistriesUnited StatesbrachytherapyCaliforniacancer centercervical cancertreatment outcomeuterine cervical neoplasms

Identifiers

PMID35917201
PMCPMC9544648
OpenAlexW4289520940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.